MD Anderson Achieves 65% Two-Year Unrelapsed Survival Rate in Phase 2 Trial of Azacitidine and Venetoclax for AML Maintenance Therapy
Unmet Needs and Clinical Background of AML Maintenance Therapy
Patients with acute myeloid leukemia (AML) suffer from high relapse rates even after achieving complete remission (CR). The importance of maintenance therapy is increasing, but currently approved standard treatments, such as Bristol Myers Squibb (BMS)'s oral azacitidine 'Onureg,' are very limited. To address this, The University of Texas MD Anderson Cancer Center conducted a Phase 2 trial (NCT04062266) of azacitidine and venetoclax combination therapy to reduce the risk of relapse. This was a strategic choice to provide a practical opportunity for survival extension for patients who are ineligible for or awaiting transplantation.
Synergistic Mechanism of Azacitidine and Venetoclax
The azacitidine (Azacitidine) used in the study induces DNA hypomethylation, activating tumor suppressor genes, while venetoclax (Venetoclax) selectively inhibits the BCL-2 protein, which blocks apoptosis. When the two drugs are used in combination, epigenetic regulation and induction of apoptosis occur simultaneously, resulting in a stronger synergistic effect than with single-agent therapy. In particular, it is clinically valuable because it can effectively eliminate treatment-resistant leukemia stem cells by blocking their survival signaling pathways. This dual-targeting mechanism is a key strategy to prevent relapse due to residual cancer cells.
Promising Survival Outcomes Demonstrated in Phase 2 Trial Results
According to the results published in 'The Lancet Haematology,' a total of 35 patients were analyzed, and a promising two-year relapse-free survival (RFS) rate of 65% was observed. Patients who received high-intensity induction therapy had a stable two-year RFS of 71%, while those who received low-intensity therapy had a two-year RFS of 52%. Despite the trial being terminated early due to slow patient enrollment, the median RFS for the entire patient population has not yet been reached. This demonstrates that the combination therapy is effective in maintaining patients' remission status for a long period.
Challenges in Safety Profile and Ease of Administration
Although excellent efficacy was confirmed, challenges remain in terms of managing adverse effects. During the trial, frequent grade 3-4 severe hematological adverse events, such as thrombocytopenia, neutropenia, and lung infection, were observed. The medical team adjusted drug dosages and designed a 28-day administration schedule to minimize toxicity, tailoring the treatment to each patient's condition. In addition, the intravenous administration of azacitidine poses a burden on patients, so future research should focus on combining it with an oral formulation to improve convenience.
Market Outlook and Competitive Landscape Analysis
The global acute myeloid leukemia (AML) treatment market is estimated at approximately $3.8 billion (approximately 5 trillion Korean won) in 2025, with an annual growth rate of 10%. With the commercialization of AbbVie and Roche's venetoclax combination therapy, the treatment paradigm will change, challenging BMS's Onureg monotherapy, which currently dominates the market. The global annual sales of venetoclax (25.8 billion in 2024) are expected to continue to grow rapidly when it enters the maintenance therapy market. Investors are closely watching whether the results of this combination trial will lead to regulatory approval and a reorganization of market share.
The results of this MD Anderson Phase 2 trial will be a key indicator in the approximately $3.8 billion annual acute myeloid leukemia (AML) treatment market, potentially challenging the existing standard maintenance therapy of Bristol Myers Squibb (BMS)'s 'Onureg' monotherapy. In particular, the specific figure of a 65% two-year relapse-free survival (RFS) demonstrates the strong competitive advantage of AbbVie and Roche's venetoclax (Venetoclax) combination therapy in the maintenance therapy market for patients who are ineligible for transplantation. In the short term, the excellent data published in The Lancet Haematology may accelerate market penetration, such as increased off-label prescriptions in clinical practice. In the medium to long term, it may lead to regulatory approval and drug listing, which will reshape the standard treatment paradigm in the field of maintenance therapy for AML in remission, an area with high unmet needs, from a single-agent approach to a two-drug combination therapy. However, it is important to note that future research on the development of oral drugs and dose optimization is essential to overcome the challenges of grade 3-4 severe hematological toxicity and the limitations of intravenous administration.
Source: ClinicalTrials.gov (api_ct)